2023 World Conference on Lung Cancer (Posters)-EP11.01. Prediction of NSCLC Immunotherapy Outcomes Across Multiple Clinical Indicators

Pdf Summary

Researchers aimed to develop a classification model to identify the signatures of non-small cell lung cancer (NSCLC) patients who respond to immunotherapy. They collected data from 538 NSCLC patients on various clinical markers related to immunotherapy. They developed several predictive models incorporating different clinical factors and evaluated their performance using various methods. <br /><br />They found that levels of certain clinical indicators, such as tumor mutational burden (TMB) and hemoglobin (HGB), were significantly different between responders and non-responders to immunotherapy. However, sex and the specific immunotherapy drug agent were not associated with clinical outcomes. <br /><br />Further analysis revealed that seven clinical indicators (chemotherapy before immunotherapy, age, stage, blood neutrophil-to-lymphocyte ratio [NLR], albumin, TMB, and fraction of copy number alteration [FCNA]) were significant prognostic factors for immunotherapy outcomes. The model incorporating these indicators had good performance in predicting the 3-year survival rate. <br /><br />The researchers developed a gradient boosting machine (GBM) model based on these seven clinical indicators. This GBM model effectively predicted immunotherapy outcomes and had comparable predictive ability to a model with 15 indicators. Different groups classified by the seven clinical indicators had significantly different survival times, and age, NLR, FCNA, and TMB were the major contributors to the model's performance. <br /><br />The findings of this study have important implications for precision immuno-oncology, as the developed GBM model can aid in classifying immunotherapy responses and guide therapeutic decisions for NSCLC patients. This represents a significant advancement in the field of precision medicine.

Asset Subtitle

Shanshan Xiao

Meta Tag

Speaker Shanshan Xiao

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

non-small cell lung cancer

NSCLC

immunotherapy

classification model

clinical markers

tumor mutational burden

hemoglobin

chemotherapy

neutrophil-to-lymphocyte ratio

precision medicine